Bio-Techne

Bio-Techne Operating Expenses

The Total Operating Expenses of Bio-Techne (TECH) as of Oct 9, 2026 is 547.18 M USD. In the previous year, Total Operating Expenses was 514.59 M USD — a change of 6.33% (higher).

Operating Expenses

547.18 MUSD

YoY

6.33%

Last updated:

Total Operating Expenses of Bio-Techne is 2026 547.18 M USD. Total Operating Expenses of Bio-Techne was 2025 514.59 M USD. It decreases by 6.33% higher compared to the previous year.

The Bio-Techne Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2019
299.28 M USD
Jan 1, 2020
306.07 M USD
Jan 1, 2021
360.53 M USD
Jan 1, 2022
426.14 M USD
Jan 1, 2023
444.93 M USD
Jan 1, 2024
489.98 M USD
Jan 1, 2025
514.59 M USD
Jan 1, 2026
547.18 M USD
The Bio-Techne Operating Expenses history
YEAROperating ExpensesYoY
547.18 MUSD+6.33%
514.59 MUSD+5.02%
489.98 MUSD+10.13%
444.93 MUSD+4.41%
426.14 MUSD+18.20%
360.53 MUSD+17.79%
306.07 MUSD+2.27%
299.28 MUSD+1.12%
295.97 MUSD+43.09%
206.84 MUSD+11.16%
186.07 MUSD+16.11%
160.25 MUSD+74.83%
91.66 MUSD—
Access this data via the Eulerpool API

Bio-Techne Stock analysis

What does Bio-Techne do? Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio-Techne stock

Total Operating Expenses of Bio-Techne is 547.18 M USD in 2026.

Total Operating Expenses of Bio-Techne changed from 514.59 M USD to 547.18 M USD, representing a 6.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Bio-Techne since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Bio-Techne historically and in real time.

Access this data via the Eulerpool API

Income Statement — Bio-Techne

All Key Metrics — Bio-Techne